Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC37,70,71”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“Several mechanisms of resistance to antiangiogenic therapy have been proposed thus far (9, 33).”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840 · cited 1×
“Total collagen content was determined by measuring hydroxyproline content of the hydrolysate samples (76).”
MethodDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Research works printed but not linked: 1
- 10.1056/NEJM198612253152606 · DOI · Paper page
Cited by
Items 101–200 of 258
Colorectal cancer initiation: Understanding early-stage disease for intervention
Jiang, C., Zhou, Q., Yi, K., Yuan, Y., & Xie, X. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216831 · Cited by 44
Conway, J. R. W., Vennin, C., Cazet, A., Herrmann, D., Murphy, K. J., Warren, S. C., Wullkopf, L., Boulghourjian, A., Zaratzian, A., Silva, A. M. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17177-5 · Cited by 34
Willumsen, N., Jørgensen, L. N., & Karsdal, M. A. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1550571 · Cited by 35
Stress responses in stromal cells and tumor homeostasis
Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 34
Molecular Mechanisms of Colorectal Liver Metastases
Tsilimigras, D. I., Ntanasis‐Stathopoulos, I., & Pawlik, T. M. (2023) · Cells · doi:10.3390/cells12121657 · Cited by 40
“However, some studies have noted that the liver may become more susceptible to metastasis post-treatment due to changes in liver sinusoid morphology and increased vascular permeability that occur following anti-VEGF therapy [111,112].”
BackgroundEpigallocatechin gallate inhibits dimethylhydrazine-induced colorectal cancer in rats
Wang, Y., Jin, H., Fang, M., Wang, X., Chen, H., Huang, S.-L., Kong, D., Li, M., Zhang, X., Sun, Y., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i17.2064 · Cited by 34
Marques-Magalhães, Â., Cruz, T., Costa, Â. M., Estêvão, D., Rios, E., Canão, P. A., Velho, S., Carneiro, F., Oliveira, M. J., & Cardoso, A. P. (2022) · Cancers · doi:10.3390/cancers14020359 · Cited by 39
Kopyeva, I., Goldner, E. C., Hoye, J. W., Yang, S., Regier, M. C., Bradford, J. C., Vera, K. R., Bretherton, R. C., Robinson, J. L., & DeForest, C. A. (2024) · Advanced Materials · doi:10.1002/adma.202404880 · Cited by 41
Jiang, Z., Shi, Y., Zhao, W., Zhou, L., Zhang, B., Xie, Y., Zhang, Y., Tan, G., & Wang, Z. (2021) · BMC Oral Health · doi:10.1186/s12903-021-01827-2 · Cited by 34
Kurkalang, S., Roy, S., Acharya, A., Mazumder, P., Mazumder, S., Patra, S., Ghosh, S., Sarkar, S., Kundu, S., Biswas, N. K., et al. (2023) · Cancer Science · doi:10.1111/cas.15979 · Cited by 32
Gu, L., Liu, Y., Jiang, C., Sun, L., & Zhou, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105087 · Cited by 33
Li, Y., Jin, G., Liu, N., Guo, H., & Xu, F. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216583 · Cited by 32
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
“In regard to anti-angiogenic therapy and solid stress, recent experimental evidence showed that anti-VEGF therapy can induce remodeling of the extracellular matrix in colorectal cancer liver metastases [224].”
BackgroundSelf-citationChen, E., Zeng, Z., & Zhou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189198 · Cited by 37
Lee, S. G., Kim, J. S., Kim, H.-J., Schlaepfer, D. D., Kim, I.-S., & Nam, J.-O. (2021) · Scientific Reports · doi:10.1038/s41598-021-88959-1 · Cited by 30
Fang, C., Dai, L., Wang, C., Fan, C., Yu, Y., Yang, L., Deng, H., & Zhou, Z. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13044 · Cited by 31
Hu, C., Zuo, Q., Jin, K., Zhao, Z., Wu, Y., Gao, J., Wang, C., Wang, Y., Zhan, W., Zhou, J., et al. (2022) · Gene · doi:10.1016/j.gene.2022.146227 · Cited by 40
Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model
El‐Hajjar, L., Jalaleddine, N., Shaito, A. A., Zibara, K., Kazan, J. M., Saghir, J. E., & El-Sabban, M. E. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.11.007 · Cited by 26
Yuan, M., Jia, Y., Xing, Y., Wang, Y., Liu, Y., Liu, X., & Liu, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.965033 · Cited by 26
“Studies have also shown that ECM participates in the invasion and metastasis of GC and promotes EMT in colorectal cancer (Rahbari et al., 2016; Yan et al., 2018).”
BackgroundReprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling
Goggins, E. S., Mironchik, Y., Kakkad, S. M., Jacob, D., Wildes, F. B., Bhujwalla, Z. M., & Krishnamachary, B. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2184145 · Cited by 24
“Studies of colorectal cancer liver metastases treated with anti-VEGF therapy have identified an increase of HA and sulfated glycosaminoglycans and increased tumor stiffness after anti-VEGF treatment, although no significant changes in collagen were detected.(62) The ECM changes observed here represent a net outcome of…”
BackgroundCha, J., Ding, E. A., Carvalho, E. M., Fowler, A., Aghi, M. K., & Kumar, S. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae355 · Cited by 38
“Chemoresistance responses, most notably to the antiangiogenic agent bevacizumab, reciprocally induce ECM remodeling (26) while driving the mesenchymal transition of GBM and speeding invasion along perivascular tracts (27), which follows routes along the basement lamina of capillaries containing…”
Kashkooli, F. M., Bhandari, A., Gu, B., Kolios, M. C., Kohandel, M., & Zhan, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114138 · Cited by 35
Identification of potential key genes in gastric cancer using bioinformatics analysis
Wang, W., He, Y., Zhao, Q., Zhao, X., & Li, Z. (2020) · Biomedical Reports · doi:10.3892/br.2020.1281 · Cited by 24
“ECM-receptor interaction serves a vital role in several types of cancer (36-38).”
BackgroundAdvances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024) · Small · doi:10.1002/smll.202403024 · Cited by 24
Inhibition of PDGF-BB reduces alkali-induced corneal neovascularization in mice
Chen, L., Wu, H., Ren, C., Liu, G., Zhang, W., Liu, W., & Lu, P. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11877 · Cited by 25
Yi, Q., Wang, J., Liu, T., Yao, Y., Loveless, I. M., Subedi, K., Toor, J. S., Adrianto, I., Xiao, H. F., Chen, B., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216149 · Cited by 25
The emerging promise of tumour mechanobiology in cancer treatment
Papavassiliou, K. A., Basdra, E. K., & Papavassiliou, A. G. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112938 · Cited by 25
Wang, Y., Shi, M., Yang, N., Zhou, X., & Xu, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.577530 · Cited by 22
“And the progression of epithelial mesenchymal transition (EMT) in colorectal cancer was activated by ECM (30).”
BackgroundInfluentialMolecular Mechanisms Involving the Sonic Hedgehog Pathway in Lung Cancer Therapy: Recent Advances
Ma, C., Hu, K., Ullah, I., Zheng, Q., Zhang, N., & Sun, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.729088 · Cited by 28
“However, angiogenesis inhibitors that target VEGF/VEGFR2 did not significantly improve the five-year survival rate for cancer patients (172, 173).”
BackgroundGalindo-Pumariño, C., Collado, M., Castillo, M. E., Barquín, J., Heras, E. R. D. L., Larriba, M. J., de Mier, G. M., Carrato, A., de la Pinta, C., & Peña, C. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116171 · Cited by 22
Magnetic resonance elastography of malignant tumors
Pagé, G., Garteiser, P., & BEERS, B. E. V. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.910036 · Cited by 23
“It has been shown that hyaluronic acid swelling also increases tumor stiffness [72].”
BackgroundSun, R., Zhao, Y., Liu, Y., Zhang, M., Qiu, Z., Ma, X., Wei, L., Lu, W., Liu, Z., & Jiang, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07697-8 · Cited by 26
“Furthermore, ECM stiffening affects drug penetration [58], genomic stability [59, 60], and immune cell in fi ltration [61, 62], thereby impacting tumor treatment ef fi cacy.”
Chen, J. L., Liu, Y., Lan, J., Liu, H., Tang, Q., Li, Z., Qiu, X., Hu, W., Xie, J., Feng, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14802 · Cited by 21
“22,23 In GBM, complex interactions among tumor cells, normal brain cells (neurons and astrocytes), and the ECM contribute to persistent tumor infiltration and treatment failure.”
BackgroundSelf-citationEngineered nanoplatform mediated gas therapy enhanced ferroptosis for tumor therapy in vivo
Xu, K., Li, K., He, Y., Mao, Y., Li, X., Zhang, L., Tan, M., Yang, Y., Luo, Z. Y., Liu, P., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.10.024 · Cited by 37
Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 24
“…circulation while lessening hypoxia by applying low levels of the antiangiogenic agents, therefore accomplishing sustained vascular normalization [252]. extending this window helps with t-cell infiltration [253], remodeled extracellular matrix [254], and reprogramming the immunosuppressive tMe.”
Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models
VandenHeuvel, S. N., Farris, H. A., Noltensmeyer, D. A., Roy, S., Donehoo, D. A., Kopetz, S., Haricharan, S., Walsh, A. J., & Raghavan, S. A. (2022) · Soft Matter · doi:10.1039/d1sm01796a · Cited by 21
Inflammatory networks cultivate cancer cell metastasis to the liver
Lee, J. W., & Beatty, G. L. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1728013 · Cited by 18
“However, one must exercise caution because some cancer treatments, including anti-vascular endothelial growth factor (VEGF) therapy [86], are known to induce liver fibrosis and may counteract therapies designed to prevent the formation of a prometastatic niche in the liver.”
BackgroundRen, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
A photothermal driven chemotherapy for the treatment of metastatic melanoma
Bhatt, H., Diwan, R., Borrego, E. A., Perez, C. A., Varela-Ramírez, A., Kumar, R., Aguilera, R. J., & Nurunnabi, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.005 · Cited by 17
Oxygen Pathology and Oxygen-Functional Materials for Therapeutics
Huo, M., Wang, L., Chen, Y., & Shi, J. (2020) · Matter · doi:10.1016/j.matt.2020.02.013 · Cited by 18
Circ_ 0115744 acts as miR-144 sponge to promote and predict the metastasis of colorectal cancer
Ma, X., Lv, L., & Xing, C. (2021) · Aging · doi:10.18632/aging.202513 · Cited by 15
“However, the overall survival of patients with CRC with liver metastasis (CRLM) remains poor [4, 5].”
BackgroundYang, Y., Wang, N., Tian, X., Wang, X., Yang, J., Leng, X., & Zhang, H. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s372048 · Cited by 16
Tian, L., Li, X., Guo, L., Huang, L., Wu, X., & Gao, W. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216027 · Cited by 16
Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
Schiffmann, L. M., Bruns, C. J., & Schmidt, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897927 · Cited by 15
“Additional therapy with polyethylene glycol conjugated (PEG) hyaluronidase in combination with VEGF inhibition led to a significant reduction of hyaluronic acid in murine colorectal liver metastases compared VEGF blockade as monotherapy (91).”
BackgroundChang, C.-W., Shih, H.-C., Cortes-Medina, M. G., Beshay, P. E., Avendano, A., Seibel, A. J., Liao, W., Tung, Y., & Song, J. W. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c15180 · Cited by 19
Ye, G., Liu, Y., Huang, L., Zhang, C., Sheng, Y., Wu, B., Wu, C., & Qi, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3823 · Cited by 15
“ECM may also promote epithelialmesenchymal transition (EMT) in colorectal cancer (13).”
BackgroundThe Biophysics of Cancer: Emerging Insights from Micro‐ and Nanoscale Tools
Beshay, P. E., Cortes-Medina, M. G., Menyhert, M. M., & Song, J. W. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100056 · Cited by 17
Shi, Q., Xu, R., Song, G., Hao, L., Xue, D., He, X., & Xia, Y. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0146-2 · Cited by 17
Huang, C., He, J., Dong, Y., Huang, L., Chen, Y., Peng, A., & Huang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.779153 · Cited by 15
Aggrecan: Approaches to Study Biophysical and Biomechanical Properties
Nia, H. T., Christine Ortiz, B., & Grodzinsky, A. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1714-3_20 · Cited by 14
Self-citationSi, Y., Li, L., Zhang, W., Liu, Q., & Liu, B. (2022) · Oncology Reports · doi:10.3892/or.2022.8397 · Cited by 13
“In a clinical setting, several novel drugs, such as anti‑VEGF agents and MEK inhibitors, have demonstrated favourable therapeutic effects; however, these are not sufficient to fulfil the need for more efficacious therapies (32,33).”
Wang, G., Wang, Y.-G., Yang, X., Zhang, Y., Lu, Y., & Li, Y. (2021) · Cancer Biomarkers · doi:10.3233/cbm-201745 · Cited by 15
“At present, bevacizumab, – an antibody against VEGF –, combined with chemotherapy is being used in the treat-ment of CRC in clinical practice and has achieved certain positive effects [17].”
The role of host response to chemotherapy: resistance, metastasis and clinical implications
Deo, A., Sleeman, J. P., & Shaked, Y. (2023) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10243-5 · Cited by 15
“Consistently, the enzymatic depletion of HA improves survival in mouse models of colon carcinoma in the context of anti-VEGF therapy and chemotherapy [110].”
Hu, J., Wang, Z., Chen, Z., Li, A., Sun, J. P., Zheng, M., Wu, J., Shen, T., Qiao, J., Li, L., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110229 · Cited by 15
Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers
Fuller, A. M., & Eisinger‐Mathason, T. S. K. (2022) · Cancers · doi:10.3390/cancers14133132 · Cited by 16
Promalignant effects of antiangiogenics in the tumor microenvironment
Peix, F., & Casanovas, O. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.003 · Cited by 13
Steins, A., Klaassen, R., Jacobs, I., Schabel, M. C., van Lier, M. G. J. T. B., Ebbing, E. A., Hectors, S. J. C. G., Tas, S. W., Maracle, C. X., Punt, C. J. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12599 · Cited by 13
“These findings are in agreement with Rahbari and colleagues demonstrating increased presence of HA following prolonged bevacizumab treatment in colorectal liver metastases (Rahbari et al., 2016).”
BackgroundResultZhu, X., Jia, W., Yan, Y., Huang, Y., & Wang, B. (2021) · European Journal of Histochemistry · doi:10.4081/ejh.2021.3246 · Cited by 15
Self-citationComparative Proteomic Analysis to Investigate the Pathogenesis of Oral Adenoid Cystic Carcinoma
Li, W., Zhang, Q., Wang, X., Wang, H., Zuo, W., Xie, H., Tang, J., Wang, M., Zeng, Z., Cai, W., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c01270 · Cited by 12
COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing’s Sarcoma
Tang, M., Liu, P., Wu, X., Gong, J., Weng, J., Gao, G., Liu, Y., & Gan, L. (2021) · BioMed Research International · doi:10.1155/2021/7453500 · Cited by 12
“The relationship between ECM and glioblastoma microenvironment is very vital in this development [25].”
BackgroundBacteria-mediated cancer therapy: A versatile bio-sapper with translational potential
Luo, M., Chen, X., Gao, H., Yang, F., Chen, J., & Qiao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.980111 · Cited by 10
“Meanwhile, accumulated ECM also creates structural obstacles physically for various cancer therapies, including chemotherapies and immunotherapies (66, 67).”
BackgroundJain, R. K., Martin, J. D., Chauhan, V. P., & Duda, D. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00008-6 · Cited by 16
Self-citationEmerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy
Jiang, S., Zhang, Z., Mao, Y., Xia, X., Luo, J., Zhang, Y., & Yuan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03933-7 · Cited by 13
“In hepatic metastasis models, post-ablation application of hydrogels carrying cGAMP or tumor antigens has maintained sustained exposure at surgical margins, enhancing dendritic cell activation in draining lymph nodes and promoting cytotoxic T-cell infiltration in adjacent liver tissue [181, 182].”
Hyaluronan-Based Hydrogels for 3D Modeling of Tumor Tissues
Alsharabasy, A. M., & Pandit, A. S. (2024) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2024.0271 · Cited by 11
“66 Additionally, HA is found both at the periphery and the interior of tumors but predominantly accumulates in the interior to counteract compressive stresses from the peripheral layer.”
Shen, C., Suo, Y., Guo, J., Su, W., Zhang, Z., Yang, S., Wu, Z., Fan, Z., Zhou, X., & Hu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430583 · Cited by 10
Zhou, Y., Guo, Y., & Wang, Y. (2022) · IET Systems Biology · doi:10.1049/syb2.12041 · Cited by 13
The Biology of Immune-Active Cancers and Their Regulatory Mechanisms
Bedognetti, D., Cesano, A., Marincola, F. M., & Wang, E. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_5 · Cited by 10
Zhang, W., Liu, J., Zhou, Y., Liu, S., Wu, J., Jiang, H., Xu, J., Mao, H., Liu, S., & Chen, B. (2024) · Poultry Science · doi:10.1016/j.psj.2024.103603 · Cited by 13
“…cell surface receptors and components of the extracellular matrix, contributing signi fi cantly to processes such as cell adhesion, migration, proliferation, and differentiation, which are crucial for cell development, tissue formation, and maintenance (Rahbari et al., 2016; San et al., 2021).”
BackgroundZheng, T., Yu, X., Yu, C., Xu, W., Fan, Z., Zhou, Y., Li, C., Wan, J., Jin, C., Jin, X., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00883-y · Cited by 11
“Such therapies can induce unanticipated vascular normalization, ECM remodeling, and improved vascular perfusion [161, 162].”
Hamada, Y., Tanoue, K., Kita, Y., Tanabe, K., Hokonohara, K., Wada, M., Hozaka, Y., Oi, H., Nakayama, C., Higashi, M., et al. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2194011 · Cited by 10
Zeng, Y., Yu, T., Zhang, S., Song, G., Meng, T., Yuan, H., & Hu, F. (2022) · Biomaterials Science · doi:10.1039/d2bm00600f · Cited by 10
Buckenmeyer, M. J., Brooks, E. A., Taylor, M. S., Orenuga, I. K., Yang, L., Holewinski, R. J., Meyer, T. J., Galloux, M., Garmendia‐Cedillos, M., Pohida, T. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-1954 · Cited by 10
Bitaraf, M., Mahmanzar, M., Zafari, N., Mohammadpour, H., Vasei, M., Matin, L. M., Kajbafzadeh, A. M., & Zolbin, M. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-22925-3 · Cited by 8
Polystyrene-Based Slippery Surfaces Enable the Generation and Easy Retrieval of Tumor Spheroids
Pulugu, P., Arya, N., Kumar, P., & Srivastava, A. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00620 · Cited by 8
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Dik, B., Coşkun, D., & Er, A. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210903120253 · Cited by 9
A Qualitative Transcriptional Signature for the Risk Assessment of Precancerous Colorectal Lesions
Guan, Q., Zeng, Q., Jiang, W., Xie, J., Cheng, J., Yan, H., He, J., Xu, Y., Guan, G., Guo, Z., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.573787 · Cited by 7
Chen, L., Xiong, Z., Zhao, H., Teng, C., Liu, H., Huang, Q., Wanggou, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889351 · Cited by 9
“Also, in colorectal cancer, the ECM participates in the process of epithelial–mesenchymal transition (EMT) and finally leads to tumor malignant progression (43).”
BackgroundSelf-citationShi, Q., Xu, R., Song, G., Hao, L., Xue, D., He, X., & Xia, Y. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00229-w · Cited by 7
Glioma Cells Secrete Collagen VI to Facilitate InvasionPreprint
Cha, J., Ding, E. A., Carvalho, E. M., Fowler, A., Aghi, M. K., & Kumar, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571198 · Cited by 7
LRPPRC promotes the progression of colorectal cancer via HIF-1ꭤ/VEGF-meditated angiogenesis
Mo, Y., Wu, S., Liu, Y., Liang, Y., Cai, Z., & Liang, L. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156223 · Cited by 7
Chen, X., Yang, C., Wang, W., He, X., Sun, H., Lyu, W., Zou, K., Fang, S., Dai, Z., & Dong, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1025163 · Cited by 8
Biologically based strategies for overcoming in vivo barriers with functional nano‐delivery systems
Ahmadzadeh, R., Taheri, S. A., Mohammadi, N., Hjazi, A. M., Menon, S. V., Kadhum, W. R., Kumar, A., Shakir, M. N., Shayan, F. K., & Shirinkami, N. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23782 · Cited by 6
Millen, J. L., Luyten, L. J., Dieu, M., Bové, H., Ameloot, M., Bongaerts, E., Demazy, C., Fransolet, M., Martens, D. S., Renard, P., et al. (2024) · Environmental Research · doi:10.1016/j.envres.2024.120214 · Cited by 7
Moserle, L., Pons, R., Martínez‐Lozano, M., Jiménez-Valerio, G., Vidal, A., Suárez, C., Trilla, E., Jimenez, J., de Torres, I. M., Carles, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911889 · Cited by 6
“Indeed, anti-VEGF therapy produces ECM remodeling and pro-aggressive tumor behavior in other tumor types (Aguilera et al, 2014; Rahbari et al, 2016).”
BackgroundWu, G., Yang, Y., Zhu, Y., Li, Y., Zhai, Z., An, L., Liu, M., Zheng, Y., Wang, Y., Zhou, Y., et al. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.742443 · Cited by 6
Ren, T., Jia, H., Wu, Q., Zhang, Y., Ma, Q., Yao, D., Gao, X., Xie, D., Xu, Z., Zhang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.829059 · Cited by 7
“demonstrated that AT1 deletion did not affect HA expression, and the abnormal deposition of ECM observed after anti-VEGF therapy was independent of the AT1 pathway (15).”
BackgroundDing, J., Zhou, H., Huang, Y.-F., Peng, J., Huang, H., Hao, Y., Zong, Z., & Ning, Z. (2022) · Biomolecules · doi:10.3390/biom12121877 · Cited by 8
“The interactions of cellular receptors and the ECM promote the development of EMT in cancerous cells and play an important role in CRC progression and metastasis [33,34].”
BackgroundSelf-citationLi, Y., Tan, M., Yang, G., Xu, Q., Wang, Q., Wang, H., & Lan, X. (2025) · Animals · doi:10.3390/ani15101365 · Cited by 5
“Additional enriched pathways, including glycosaminoglycan biosynthesis and folate-mediated one-carbon metabolism, are involved in cell proliferation, migration, and survival—processes often dysregulated in cancer [70–74].”
Integrating Nanorobotics with Biophysics for Cancer Treatment
Malviya, R., Yadav, D., Sundram, S., Kadry, S., & VIRK, G. S. (2024) · Institute of Physics eBooks · doi:10.1088/978-0-7503-6019-7 · Cited by 4
Improving treatment of liver metastases by targeting nonangiogenic mechanisms
Emblem, K. E., & Jain, R. K. (2016) · Nature Medicine · doi:10.1038/nm.4228 · Cited by 5
Self-citationNormalizing the Tumor Microenvironment for Radiosensitization
Martin, J. D., & Jain, R. K. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_12 · Cited by 5
Self-citationYeow, Y. L., Wu, J., Wang, X., Winteringham, L. N., Feindel, K. W., Tirnitz‐Parker, J. E. E., Leedman, P. J., Ganß, R., & Hamzah, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837234 · Cited by 5
Liu, Y., Han, Y., Guo, Z., Zhang, Y., Xu, X., Qi, W., Xu, M., & Li, J. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00970-0 · Cited by 4
“Furthermore, the ECM represents a potential therapeutic target, actively involved in tumor treatment and prognostic monitoring [19, 20].”
Vonica, R. C., Morgovan, C., Butucă, A., Pumnea, M., Cipăian, R. C., Frum, A., Dobrea, C. M., Vonica-Țincu, A. L., Pacnejer, A.-M., Batâr, F., et al. (2025) · Cancers · doi:10.3390/cancers17040663 · Cited by 4
“Vascular endothelial growth factor (VEGF) withdrawal leads to an increase in extracellular matrix (ECM) deposition in malignant tumors [13,14].”
Aggrecan: Approaches to Study Biophysical and Biomechanical Properties
Nia, H. T., Christine Ortiz, B., & Grodzinsky, A. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1398-6_17 · Cited by 4
Self-citationShao, F., Jin, K., Li, B., Liu, Z., Zeng, H., Wang, Y., Zhu, Y., Xu, L., Xu, J., Wang, Z., et al. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.07.006 · Cited by 3
Wang, K., Liao, P.-Y., Chang, W., Yang, C.-R., Su, Y., Wu, P., Wu, Y., Hung, Y., Akhtar, N., Lai, H., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1281067 · Cited by 4
Wei, P., Li, J., Cheng, X., Lu, Y., Xia, Q., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1718894 · Cited by 5
“In CRC, compensatory FGF/FGFR and HGF/MET signaling, along with vessel co-option and in fi ltrative transformation, are observed after anti-VEGF therapy, particularly in liver metastases (89, 90).”
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer
Wagner, V., Bousset, L., Ascensão-Ferreira, M., Sun, B., Avila, J. E. B., Kaizeler, A., Martins-Silva, R., Rahbari, M., Fernández-Vaquero, M., Haston, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71564-z · Cited by 3
“MC38 mouse cells were a gift from Nuh Rahbari and have been described previously 41,42 .”
Metadata
- Authors
- Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., Heishi, T., Martin, J. D., Huang, Y., Maimon, N., Reissfelder, C., Weitz, J., Boucher, Y., Clark, J. W., Grodzinsky, A. J., Duda, D. G., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- University Hospital Carl Gustav Carus (DE)
- Department of General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany.
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- Fukumura, Dai
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-10-12
- Volume
- 8
- Issue
- 360
- Pages
- 360ra135-360ra135
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5457741
- OpenAlex
- W2530012709
- Cited by
- 258
- References
- 78
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 24 · 2023: 28 · 2022: 37 · 2021: 40 · 2020: 30 · 2019: 21 · 2018: 19 · 2017: 16 · 2016: 3
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- NIH (CA080124, T32DK007191, CA126642, CA197743, CA096915, CA139168, CA159258, CA098706, CA173518)
- American Cancer Society (120733-RSG-11-073-01-TBG)
- German Research Foundation
- Foundation for Science and Technology
- Portuguese Human Potential Operational Program/European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anti-VEGF therapy, colorectal liver metastases, extracellular matrix remodeling, hyaluronic acid, sulfated glycosaminoglycans, tumor stiffness, tumor hypoxia, bevacizumab, acquired drug resistance, tumor perfusion, combination chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Animals, Hypoxia, Biomechanical Phenomena, Extracellular Matrix, Glycosaminoglycans, Humans, Hyaluronic Acid, Liver Neoplasms, Mice, Inbred BALB C, Mice, Inbred C57BL, Colorectal Neoplasms, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.